is an analogue of thalidomide. The mechanism of action has not been fully elucidated. While, its several characters have been discovered, including anti-tumor, anti-angiogenesis, erythropoiesis and immune regulation. Lenalidomide helps inhibit the proliferation of certain hematopoietic tumor cells. For example, multiple myeloma plasma cells and tumor cells with chromosome 5 deletion. Meanwhile, Lenalidomide is able to enhance the immune function mediated by T cells and natural killer cells, increase the number of natural killer T cells, inhibit angiogenesis by preventing the migration and adhesion of endothelial cells and block the formation of microvessels, increase the production of fetal hemoglobin by CD34 + hematopoietic stem cells and inhibit the production of pro-inflammatory cytokines (such as TNF-α and IL-6) produced by monocytes.
Lenalidomide Cardiac electrophysiology
In a comprehensive QTc study of randomized placebo and positive controls, the effect of lenalidomide on QT interval was evaluated on 60 healthy male subjects. The effect of lenalidomide on the QTc interval was not clinically significant at a maximum recommended dose of 2x (50 mg). The upper limit of the bilateral 90% CI with the difference between the lenalidomide group and the placebo group was less than 10 ms.